Treanda (bendamustine
hydrochloride) for Injection
Cephalon Inc (Frazer, PA) recently
received FDA approval for Treanda for
the treatment of patients with indolent
B-cell non-Hodgkin's lymphoma (NHL)
that has progressed during or within
6 months of treatment with rituximab
or a rituximab-containing regimen.
Treanda has a convenient dosing
schedule as a treatment for indolent
NHL. An intravenous infusion takes 60
minutes and can be administered in an
outpatient setting, reducing the time
it takes for patients to be treated. The
recommended dose for indolent NHL is
120 mg/m
2 administered on days 1 and
2 of a 21-day cycle, for up to 8 cycles.
The product also is indicated for the
treatment of patients with chronic lymphocytic
leukemia, a slowly progressing
blood and bone marrow disease.
For more information, call 800-896-
5855, or visit
www.cephalon.com.
Cardene I.V. (nicardipine
hydrochloride)
EKR Therapeutics Inc (Bedminster,
NJ) recently received FDA approval
for double concentration of Cardene
I.V. premixed injection. These patented
200-mL ready-to-use intravenous (IV)
bags contain 40 mg of the calcium
channel blocker nicardipine hydrochloride
(0.2 mg/mL) in either dextrose or
sodium chloride. In August 2008, the
FDA approved a single concentration
of Cardene I.V. ready-to-use IV bags.
The single concentration consists of
200-mL premixed bags containing 20
mg of nicardipine hydrochloride (0.1
mg/mL) in either dextrose or sodium
chloride. The product is indicated for
the short-term treatment of hypertension
when oral therapy is not feasible or
desirable. Cardene I.V. dosage must be
individualized depending on the severity
of hypertension and the response
of the patient during dosing. Blood
pressure should be monitored both
during and after the infusion. For more
information, visit
www.cardeneiv.com,
or call 877-207-5802.
DoseTrac Infusion Management Software
B. Braun Medical Inc (Bethlehem, PA)
recently launched DoseTrac Infusion
Management Software with Inbound
Admission, Discharge, and Transfer
(ADT) Interface capabilities. The ADT
Interface capability makes connectivity
easier and less expensive. It is one
of a series of connectivity programs
the company expects to introduce for
DoseTrac to support better communication
among clinical, administrative,
and ancillary applications. DoseTrac
with ADT Interface receives real-time
notification of patient arrivals, movements,
and departures to help improve
the efficiency of the services provided
by clinicians. In-depth patient information
and locations are received and
posted in real time to specific views and
reports within DoseTrac to help health
care professionals better interpret and
make use of infusion information. For
more information, call 800-227-2862, or
visit
www.bbraunusa.com.
Rocuronium Bromide Injection
Teva Pharmaceuticals (North Wales,
PA) recently received FDA approval
for Rocuronium Bromide Injection.
The product is AP-rated to Organon
USA Inc's Zemuron. The product is a
nondepolarizing neuromuscular blocking
agent indicated as an adjunct to
general anesthesia to facilitate both
rapid sequence and routine tracheal
intubation and to provide skeletal
muscle relaxation during surgery or
mechanical ventilation. Rocuronium
Bromide Injection is for intravenous
use only. The product should only be
administered by experienced clinicians
or trained individuals supervised by
an experienced clinician familiar with
use, actions, characteristics, and complications
of neuromuscular blocking
agents. Doses of Rocuronium Bromide
Injection should be individualized, and
a peripheral nerve stimulator should
be used to monitor drug effect, need
for additional doses, adequacy of spontaneous
recovery or antagonism, and
to decrease the complications of overdosage
if additional doses are administered.
The product is available in
multiple-dose glass vials of 5 mL, containing
50 mg Rocuronium Bromide (10
mg/mL), and 10 mL containing 100 mg
Rocuronium Bromide (10 mg/mL). For
more information, call 888-TEVA USA
(888-838-2872), or visit
www.tevausa.com.
